The Journal of Clinical Endocrinology & Metabolism · 2012 · 47 citations · 28 references
MedicineCancer BiologyOncologyBreast OncologyChemotherapyMolecular OncologyCytotoxic ChemotherapyGrowth Factor SignalingGrowth HormoneHormonal Cancer TherapyHormonal TherapySignal Transduction In CancerBreast Cancer ChemotherapyChemotherapy-induced ApoptosisEstrogen Receptor ExpressionEstrogen Receptor SignalingGlutathione S-transferase ActivityGrowth Hormone ReceptorsHormone Receptor - Positive Breast CancerHormone-induced Apoptosis Resistance
CONTEXT: GH and IGF-I play a role in breast cancer (BC) development. We previously demonstrated that GH protects the estrogen receptor (ER) positive BC-derived MCF7 cell line toward the cytotoxic effects of doxorubicin (D), independently of IGF-I. This issue may be important in ER negative BC cells that are more aggressive and more likely to develop chemoresistance. AIM OF THE STUDY: The aim of this study was to evaluate whether GH may impact chemoresistance phenotype of ER-negative BC-derived MDA-MB-231 cell line and investigate the possible mechanisms implicated in the protective action of GH toward the cytotoxic effects of D in both ER-positive and ER-negative BC-derived cell lines. RESULTS: GH protects ER-negative MDA-MB-231 cells from the cytotoxic effects of D and GH receptor antagonist pegvisomant reduces GH-induced DNA synthesis also in these cells. In both MDA-MB-231 and MCF7 cells, GH does not revert D-induced G2/M accumulation but significantly reduces basal and D-induced apoptosis, an effect blocked by pegvisomant. Glutathione S-transferase activity is not implicated in the protective effects of GH, whereas D-induced apoptosis depends on c-Jun N terminal kinase (JNK) activation. GH reduces both basal and D-stimulated JNK transcriptional activity and phosphorylation. CONCLUSIONS: In human BC cell lines, GH directly promotes resistance to apoptosis induced by chemotherapeutic drugs independently of ER expression by modulating JNK, further broadening the concept that GH excess may hamper cytotoxic BC treatment. These findings support the hypothesis that blocking GH receptor may be viewed as a potential new therapeutic approach to overcome chemoresistance, especially in ER-negative BC.
28
Breast Tumor Cell Lines From Pleural Effusions2
Relda Cailleau, Russell K. Young, Matilde Olivé et al. · JNCI Journal of the National Cancer Institute · 1974 · 1K citations · Full text
Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells.
Frank A. Fornari, Joyce K. Randolph, Jack C. Yalowich et al. · Molecular Pharmacology · 1994 · 442 citations
Adrian V. Lee, James G. Jackson, Jennifer L. Gooch et al. · Molecular Endocrinology · 1999 · 324 citations
Stefan N. Constantinescu, Tzvia Keren, Merav Socolovsky et al. · Proceedings of the National Academy of Sciences · 2001 · 266 citations · Full text